ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Membranous Glomerulonephritis

Kidney Disease trials near Montréal, QC, CAN:

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD)....

Enrolling
Kidney Disease
Drug: Placebo matching GSK4771261
Drug: GSK4771261

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

MontrEal, Quebec, Canada and 13 other locations

Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors ...

Enrolling
Kidney Failure, Chronic
Diabetic Nephropathies
Drug: Placebo
Drug: Sotagliflozin

Phase 3

Alessandro Doria

Montreal, Quebec, Canada and 17 other locations

baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney...

Not yet enrolling
Chronic Kidney Disease and Hypertension
Drug: Baxdrostat/dapagliflozin
Drug: Baxdrostat/Placebo

Phase 2

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 67 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Montreal, Canada and 330 other locations

with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Part...

Begins enrollment this month
Chronic Kidney Disease
Atherosclerosis Cardiovascular Disease
Drug: Orforglipron
Drug: Placebo

Phase 3

Lilly
Lilly

Montreal, Canada and 518 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Active, not recruiting
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 295 other locations

This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medici...

Begins enrollment this month
Chronic Kidney Disease
Drug: Placebo
Drug: Empagliflozin

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Montreal, Quebec, Canada and 100 other locations

and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...

Enrolling
Chronic Kidney Disease and Hypertension
Drug: Baxdrostat/dapagliflozin
Drug: Placebo/dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 716 other locations

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Active, not recruiting
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Montreal, Quebec, Canada and 166 other locations

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)

Phase 3

Bayer
Bayer

Montreal, Quebec, Canada and 170 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems